Evidence map›Paper›PMID 35693772›Full record

ArticleFrontiers in immunology2022

Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation.

Lidan Zhu, Jia Liu, Peiyan Kong, Shichun Gao, Lu Wang, Huanfeng Liu, Cheng Zhang, Li Gao, Yimei Feng, Ting Chen and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Lidan ZhuMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Jia LiuMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Peiyan KongMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Shichun GaoMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Lu WangMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Huanfeng LiuMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Cheng ZhangMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Li GaoMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Yimei FengMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Ting ChenMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Lei GaoMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Xi ZhangMedical Center of Hematology, The Second Affiliated Hospital, Army Medical University, Chongqing, China.
Army Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelet graft failure (PGF) is a frequent and serious complication after Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and lacks effective treatment strategies, which could affect the prognosis of patients and even cause death. The exact underlying mechanism of PGF remains unclear, and lacks standard treatment. Here, we conduct a retrospective study to evaluate the efficacy and safety of avatrombopag combined with mesenchymal stem cells (MSCs) in 16 patients with thrombocytopenia after allo-HSCT. Patients were administered the following treatment regimen: 20 mg/d avatrombopag; if the PLT count was less than 50×10

Indexed as

Hematopoietic Stem Cell TransplantationMesenchymal Stem CellsThrombocytopeniaHumansQuality of LifeRetrospective StudiesThiazolesThiophenesavatrombopagThiazolesThiophenesallogeneic hematopoietic stem cell transplantation (AlloHCT)avatrombopagsafetythrombocytopeniaumbilical cord MSCs

Identifiers

PMID35693772
PMCPMC9184517
OpenAlexW4281703934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.